Diagnostic company Cue Health announced on Thursday that it will create an Omicron-genotyping COVID-19 test.
The test will be used in professional care settings to specifically detect the Omicron variant in nasal samples. The work is part of a partnership with HHS’ Biomedical Advanced Research and Development Authority (BARDA).
"An Omicron-specific test will assist clinicians in providing...
